Previous 10 | Next 10 |
Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel in psoriasis expected in 2024 Reviva has filed composition of matter patent for ...
2023-05-04 10:00:25 ET Gainers: Soligenix ( SNGX ) +117% . ZimVie ( ZIMV ) +27% . Lantheus ( LNTH ) +14% . MiNK Therapeutics ( INKT ) +16% . Reviva Pharmaceuticals ( RVPH ) +10% . Losers: Sensus Healthcare ( SRTS ...
CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous s...
Multifaceted activity of brilaroxazine supports potential for improvement in behavioral symptoms as well as accompanying neuroinflammation This proof-of-concept data supported the initial clinical development of brilaroxazine and reinforces the clinical profile demonstrated in the Phase...
CUPERTINO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
CUPERTINO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
2023-03-30 07:51:38 ET Reviva Pharmaceuticals press release ( NASDAQ: RVPH ): FY GAAP EPS of -$1.25 misses by $0.16 . As of December 31, 2022, the Company’s cash and cash equivalents totaled approximately $18.5 million compared to approximately $29.7 million a...
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – - Completed majority of non-clinical and clinical prelaunch measures for brilaroxazine New Drug Application (NDA) submission – - Pos...
CUPERTINO, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
Cupertino, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...
News, Short Squeeze, Breakout and More Instantly...
Reviva Pharmaceuticals Holdings Inc. Company Name:
RVPH Stock Symbol:
NASDAQ Market:
Reviva Pharmaceuticals Holdings Inc. Website:
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also been granted in k...
2024-06-11 08:15:03 ET H.C. Wainwright analyst issues BUY recommendation for RVPH on June 11, 2024 06:40AM ET. The previous analyst recommendation was Buy. RVPH was trading at $1.45 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...